Wall Street analysts forecast that Tcr2 Therapeutics Inc (NASDAQ:TCRR) will report earnings per share of ($0.65) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Tcr2 Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.62) and the lowest estimate coming in at ($0.67). Tcr2 Therapeutics reported earnings per share of ($16.22) in the same quarter last year, which would suggest a positive year-over-year growth rate of 96%. The business is scheduled to report its next earnings report on Monday, April 6th.
On average, analysts expect that Tcr2 Therapeutics will report full-year earnings of ($5.10) per share for the current fiscal year, with EPS estimates ranging from ($6.56) to ($4.32). For the next fiscal year, analysts expect that the company will report earnings of ($2.76) per share, with EPS estimates ranging from ($3.21) to ($1.91). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Tcr2 Therapeutics.
Several equities research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $19.00 price objective on shares of Tcr2 Therapeutics in a research report on Wednesday, December 11th. Zacks Investment Research cut shares of Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, ValuEngine upgraded shares of Tcr2 Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, February 12th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $25.00.
In related news, major shareholder Morana Jovan-Embiricos sold 7,743 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $17.65, for a total value of $136,663.95. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 150,623 shares of company stock worth $2,656,646 in the last 90 days. 39.07% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in TCRR. BlackRock Inc. purchased a new position in Tcr2 Therapeutics during the second quarter worth $1,511,000. Vanguard Group Inc. purchased a new position in Tcr2 Therapeutics during the second quarter worth $1,070,000. Rhumbline Advisers purchased a new position in Tcr2 Therapeutics during the third quarter worth $162,000. First Trust Advisors LP purchased a new position in Tcr2 Therapeutics during the third quarter worth $474,000. Finally, State Street Corp boosted its stake in Tcr2 Therapeutics by 1,033.6% during the third quarter. State Street Corp now owns 166,634 shares of the company’s stock worth $2,505,000 after buying an additional 151,934 shares during the period. Institutional investors own 58.99% of the company’s stock.
Tcr2 Therapeutics Company Profile
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.
See Also: How To Calculate Debt-to-Equity Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.